This year’s advanced psychopharmacology preconference is designed to give an overview of the “four most exciting things happening in Psychiatry”. You will leave this pre-conference energized and ready to take on the next 4 days of continued psychopharmacology education, one step ahead of your peers.
Click to Read More
This year’s preconference is designed to give an overview of reproductive psychiatry, developed in partnership with the International Society for Reproductive Psychiatry (ISRP). You will leave this pre-conference with an expanded knowledge of women’s health and reproductive psychiatry throughout the lifespan.
Click to Read More
The co-chairs of the 36th annual Psych Congress will commence the conference by introducing two remarkable presentations and priming attendees for an engaging and informative week ahead.
Dr. Jennifer Mascaro will explore the powerful relationship between language, treatment adherence and patient outcomes, highlighting the critical importance of using inclusive language and avoiding stigmatizing terms in clinical settings to promote better health outcomes and patient satisfaction.
Join Dr. Kay Redfield Jamison, internationally renowned clinical psychologist, and award-winning author with lived experience, as she delves into the enduring foundations of psychotherapy and explores the essential traits of effective healers.
Developed in partnership with Depression and Bipolar Support Alliance
Psych Congress has partnered with the Depression and Bipolar Support Alliance to deliver advanced education on mood disorders including Depression and Bipolar Disorder, which affect over 21 million Americans and account for over 50% of the nation’s suicides every year.
This session will explore the complex landscape of end-of-life care and the debate surrounding the values of autonomy and comfort. The presentation will delve into how language, such as euthanasia and medical aid in dying, shapes the clinical and political realities of end-of-life care, and how this framing impacts patient and family decision-making. The session will also address the primary concerns of those who oppose the determination of the timing of death and distinguish among palliative sedation, euthanasia, and physician-assisted suicide. Attendees will leave with a deeper understanding of how to navigate the legal and ethical considerations of end-of-life care, with a focus on defining what constitutes a "good death."
While benzodiazepines can be highly effective in managing symptoms, they are often viewed as addictive and dangerous, leading many patients to avoid seeking treatment altogether. This session will explore the stigma associated with the use of benzodiazepines in the treatment of anxiety and other mental health disorders.
Click to Read More
A new feature at Psych Congress in 2023, each Foundations in Psychopharmacology session will dive deep into one specific therapeutic drug class, such as antidepressants or antipsychotics. These sessions are distinct in their foundational emphasis on both long-standing medications often appropriate as first-line therapies, as well as additional first-line options and adjunctive treatments. Foundations sessions may be particularly valuable for early-career psychopharmacologists and those looking for a detailed look at the when and the why of medication selection as well as access-related challenges and considerations that may affect treatment decisions.
Click to Read More
The phenomenon of prolonged grief after suicide loss is a significant and often debilitating challenge for many individuals and families. In this session we will explore the latest research and innovative treatments for addressing this complex and multifaceted issue. Through a focus on restoring hope and promoting healing, we will discuss how to effectively support those who are struggling with prolonged grief after suicide loss and empower them to move forward with resilience and optimism.
Developed in partnership with the American Foundation for Suicide Prevention.
In this session, we will explore the underlying mechanisms of agitation and how it manifests in different psychiatric disorders, with a focus on schizophrenia and bipolar disorder. We will discuss evidence-based interventions for managing agitation, including pharmacotherapy and psychotherapeutic approaches. Attendees will gain a deeper understanding of the impact of agitation on patients and learn practical strategies for effectively managing agitation in psychiatric practice.
Join us for an engaging MasterClass educational session designed to equip medical professionals with the latest insights and practical skills for enhancing the management of major depressive disorder (MDD). Expert faculty will discuss the of the role of neuroplasticity in MDD and its implications for disease management, particularly in relation to digital therapeutics. Dive into the interpretation of the most recent clinical data for digital therapeutic strategies in the context of MDD, and learn about their efficacy to cognitive behavioral therapy. Additionally, participants will learn how to implement strategies that address barriers to the integration of digital therapeutics into clinical practice. By the end of the session, attendees will have the tools to optimize MDD management, incorporating cutting-edge approaches and overcoming obstacles. Don't miss this opportunity to enhance your understanding of MDD treatment and improve patient outcomes.
Click to Read More
The management of major depressive disorder (MDD) is an ongoing clinical challenge, especially considering the large proportion of patients who experience an inadequate response to initial antidepressant monotherapy. These patients experience a substantial burden with higher functional impairments and poorer clinical outcomes. In this MasterClass session, expert faculty will delve into the assessment of the prevalence and burden of poor response in individuals with MDD, exploring the limitations of traditional antidepressants that often contribute to this issue, offering insights into the factors underlying poor response. Participants will gain a profound understanding of the role of glutamatergic signaling in the pathophysiology of MDD and how this knowledge translates into potential therapeutic targets. Expert faculty will critically evaluate the mechanisms of action, pharmacokinetic profiles, and the latest clinical data associated with newer and emerging glutamatergic pharmacotherapies.
Click to Read More
This MasterClass session aims to equip participants with the knowledge and skills to better understand the diagnostic challenges associated with bipolar disorder (BD), including differentiating BD1, BD2, and MDD. Expert faculty will highlight the impact of cardiometabolic burden on treatment adherence and overall outcomes in patients with BD, providing practical guidance on how to mitigate these risks. Participants will also be introduced to the limitations of traditional antipsychotic agents and off-label therapies in BD, as well as the latest clinical evidence and mechanisms of action associated with newer/novel therapies. The session will conclude by evaluating the potential of these newer/novel therapies to mitigate cardiometabolic adverse effects in patients with BD, equipping participants to make informed decisions about which therapy to prescribe in individual cases.
Click to Read More
Dr. Christine Moutier, Chief Medical Officer of ASFP will kick off our keynote address by discussing their mission to save lives and bring hope to those affected by suicide. Following her presentation Music Neighbors will delve into the power of music as a tool for processing trauma and addressing mental health issues. Through the lens of local musicians, we will experience an iconic Nashville Songwriters' rounds, where artists will share personal stories and perform songs that have helped them to heal. By hearing from these artists, we will explore how music can provide a cathartic release, self-expression, and emotional processing. Join us for this inspiring and thought-provoking session that highlights the intersection of music and mental health.
Developed in partnership with AFSP.
Through our continued partnership with the American Foundation for Suicide Prevention, we are proud to announce that we will host an Out of the Darkness Community Walk at this year's Psych Congress in Nashville. Learn more, donate, and register for the walk here: www.afsp.org/psychcongress
As the global population continues to age, it is becoming increasingly important to identify effective coping strategies for older individuals. This session will explore the concept of resilience and how it relates to aging, including the potential challenges that older adults may face and the coping strategies that may be particularly helpful for this population. With a focus on the challenges faced by aging patients, we will explore how to identify and bolster coping strategies that can help patients maintain resilience in the face of those challenges.
Click to Read More
In this session, we will explore the latest emerging technologies and digital tools that can help manage Attention Deficit Hyperactivity Disorder (ADHD). We will discuss how these tools can improve attention, focus, and organization, and reduce symptoms of ADHD. We will also explore how digital tools such as mobile apps, wearables, and virtual reality can help individuals with ADHD manage their symptoms and improve their overall quality of life. This session is ideal for those looking to stay up-to-date on the latest advances in ADHD treatment and management.
A new feature at Psych Congress in 2023, each Foundations in Psychopharmacology session will dive deep into one specific therapeutic drug class, such as antidepressants or antipsychotics. These sessions are distinct in their foundational emphasis on both long-standing medications often appropriate as first-line therapies, as well as additional first-line options and adjunctive treatments. Foundations sessions may be particularly valuable for early-career psychopharmacologists and those looking for a detailed look at the when and the why of medication selection as well as access-related challenges and considerations that may affect treatment decisions.
Click to Read More
Reproductive psychiatry focuses on the management of psychiatric disorders in women during their reproductive years. The session will cover evidence-based integrative approaches to reproductive psychiatry. Participants will learn how these integrative treatments can support women's mental health during the perinatal period, and how to incorporate them into clinical practice. Overall, this session will provide valuable insights into a comprehensive approach to reproductive psychiatry that emphasizes the mind-body connection and individualized care.
Developed in partnership with The International Society of Reproductive Psychiatry
Click to Read More
Designed to provide practical solutions to some of the most challenging patient cases, Solving Clinical Challenges sessions put our most experienced faculty on the spot to answer the question—what would you do? Exploring complex scenarios associated with real patients, our clinical panel will interact and collaborate to share insights and expertise on diagnostic challenges, psychopharmacologic and psychotherapeutic approaches, and multidisciplinary care. Practical take-aways will enable clinicians to apply advanced approaches to similarly complex patients, enhancing overall care delivery, and optimizing patient outcomes.
Click to Read More
Many patients with bipolar disorder struggle to adhere to prescribed treatments because of their complex daily regimens, adverse effects (AEs), and various patient-specific factors. Fortunately, several antipsychotics for BD-I have long-acting injectable (LAI) formulations, which have been shown to improve treatment adherence beyond that of standard oral formulations. Participate in this session to gain a comprehensive understanding of the safety, efficacy, and pharmacokinetics of the currently available long-acting injectable (LAI) antipsychotics for BD-I. Learn from expert faculty how to evaluate the distinctive characteristics of patients with BD-I who might benefit from LAI treatment. By integrating patient-centered care strategies, including motivational interviewing, attendees will acquire the tools to foster collaborative communication and enhance treatment acceptance among patients with BD-I.
Click to Read More
Major depressive disorder (MDD) is plagued by inadequate treatment response and associated with significant negative quality of life (QoL) and high costs; it is estimated that less than half of patients with MDD respond to antidepressant therapy and only half of patients will ever achieve remission. This MasterClass session will explore the burden and unmet needs associated with MDD, with a special focus on patients who exhibit inadequate or partial responses to antidepressant monotherapy. In this session you will learn to identify and evaluate patient characteristics that signal a need for adjunctive treatment, enabling them to make informed decisions for tailored care. Through an in-depth exploration of the mechanisms of approved atypical antipsychotics in the context of adjunctive MDD treatment, you will gain a comprehensive understanding of how these agents impact multiple receptor systems. Furthermore, expert faculty will critically evaluate the efficacy and safety of atypical antipsychotics approved for adjunctive MDD treatment, ensuring that participants are equipped with the latest evidence-based insights.
Click to Read More
This MasterClass session is designed to help healthcare professionals better understand the spectrum of potential consequences beyond physical appearance for individuals with TD, including negative impacts on physical, cognitive, and psychosocial functioning. Participants will learn how to implement optimal assessment strategies for the detection and evaluation of TD and will be introduced to the VMAT-2 inhibitors approved for the condition. The session will also provide an in-depth evaluation of the practical differences between these novel treatments, equipping participants to make informed decisions about which therapy to prescribe in individual cases. By the end of the session, participants will have gained valuable knowledge and skills for providing effective care for patients with TD, improving outcomes and quality of life for this patient population.
Click to Read More
The stimulant crisis has reached a critical point, necessitating a comprehensive understanding of the challenges it presents. This session will explore the implications of recent FDA warnings in stimulant labels, strategies to manage the growing demand, and the ongoing medication shortage.
Depression is a complex and multifaceted mental health condition that affects millions of people around the world. In recent years, there has been an explosion of research aimed at better understanding the underlying causes of depression, as well as developing more effective treatments for the disorder. This session will provide an overview of the state of the science of depression, drawing on the latest findings and what is on the horizon.
Click to Read More
This session will explore the rapidly-evolving landscape of technology—including digital therapeutics and Artificial Intelligence—and the potential for technology to revolutionize the field of psychiatry. Through an expert-led presentation, this session will provide attendees with a comprehensive understanding of the latest technological developments and implications for the future of psychiatry.
The session will cover the most up-to-date information on the therapeutic potential of psychedelic substances and the latest findings on their effects on mental health and well-being.
Developed in partnership with SANA
Click to Read More
In this session, we will discuss the key concepts of statistical significance and clinical relevance in clinical trial results. You will gain an understanding of the difference between p-value and effect size, and how to calculate effect size. By the end of this session, you will have a clear understanding of the importance of these concepts in interpreting clinical trial results and be better equipped to differentiate between statistically significant results and those with clinical relevance. This session is essential for anyone involved in clinical research or who needs to interpret clinical trial results.
The COVID-19 pandemic has caused significant disruptions in our daily lives, triggering a surge in anxiety and stress levels. This session will focus on exploring effective treatment strategies for managing anxiety, specifically for Generalized Anxiety Disorder (GAD), Obsessive Compulsive Disorder (OCD), and Agoraphobia. We will discuss the role of behavioral therapy and medication treatment in managing anxiety symptoms, including the use of virtual therapy options. Additionally, we will explore reengagement with society and practical tips for overcoming fear and anxiety in social situations.
In recent years, there has been growing interest in the relationship between nutrition and mental health. This session will explore the emerging field of Nutritional and Metabolic Psychiatry and discuss the potential of leveraging diet as a key aspect of psychiatric treatment. We will review the latest research on the impact of diet on mental health and examine the mechanisms by which specific nutrients may influence brain function and behavior. We will discuss the role of insulin resistance, ketogenic diets, and micronutrient deficiencies across multiple psychiatric disorders. The practical considerations for implementing dietary and nutritional interventions in psychiatric practice will be discussed. By the end of the session, attendees will have a better understanding of the role of diet and nutritional supplementation to augment medication management.
This session aims to explore the importance of early identification and intervention in the management of patients experiencing their initial schizophrenic episode. The session will cover key strategies for assessing and diagnosing early symptoms, including prodromal and attenuated psychotic symptoms. We will also discuss evidence-based interventions, including pharmacological and non-pharmacological treatments, that can improve patient outcomes and reduce the risk of relapse.
Click to Read More
This session will explore the complex and often misunderstood relationship between postpartum psychosis, thoughts of harming the infant and infanticide. Although it is not uncommon for women with postpartum mood or anxiety disorders to experience thoughts of harming their infant, the overwhelming majority of women do not engage in violent behavior. This session provides an understanding of the risk factors, warning signs, and treatment options associated with infanticide. Attendees will leave this session with a greater appreciation for the complexity of diagnosing and treating women with postpartum psychosis while preserving the maternal infant bond.
Developed in partnership with The International Society of Reproductive Psychiatry
Click to Read More
The use of Ketamine as a potential treatment for depression and PTSD has gained significant attention in recent years. The session will provide an overview of the mechanism of action and pharmacology of Ketamine, the evidence supporting its use in these disorders, and provide practical tips for the use of Ketamine in clinical practice, including dosing, administration, monitoring, and patient selection.
Click to Read More
Depressive disorders are a collection of debilitating mental illnesses that affect millions of people worldwide. While traditional antidepressants can be effective, they can take weeks or even months to start working, leaving patients suffering in the meantime. Rapid-acting antidepressants are a promising new approach to treating depressive disorders that can provide relief in a matter of hours or days rather than weeks. This session will explore the latest innovations in rapid-acting antidepressant treatments, including ketamine, psilocybin, and other novel compounds. We will discuss the mechanisms of action of these drugs, their efficacy in clinical trials, and the potential risks and side effects. We will also explore the ethical implications of using these powerful drugs to treat mental illness.
Click to Read More
In today's healthcare landscape, it is essential to incorporate the patient's voice in shared decision-making, where the clinician acts as an advisor. This approach ensures that the best practices are developed by incorporating the patient's perspective. This session aims to provide clinicians with the necessary skills to incorporate patient perspectives and develop treatment plans that align with the patient's needs. We will challenge clinicians to consider how they can transform their approach to patient care and create a more patient-centered practice.
Developed in partnership with Depression and Bipolar Support Alliance
Click to Read More
Personality disorders are prevalent and often difficult to recognize mental health conditions, today we will be discussing screening and assessment tools. The presentation will cover various tools and techniques for screening and assessing personality disorders, including self-report measures, clinician-administered interviews, and objective measures. The importance of early detection and diagnosis of personality disorders in order to improve treatment outcomes and long-term prognosis will be highlighted.
Click to Read More
Obsessive Compulsive Disorder (OCD) is a common and disabling disorder that often manifests in childhood. It is characterized by intrusive and distressing thoughts, images, or impulses (obsessions) that are accompanied by repetitive behaviors or mental acts (compulsions) aimed at reducing the anxiety caused by the obsessions. The management of OCD in children can be challenging, and early diagnosis and treatment are critical for preventing long-term disability.
Click to Read More
Clinicians who treat patients with a history of mania historically turned to lithium as the go-to mood stabilizer. More recently, concerns about renal and other adverse effects have led some to approach this treatment option with caution. This presentation aims to provide clinicians with the most up-to-date information on lithium's role in treating bipolar patients, including dosing, kinetics, and target serum levels. Additionally, the presentation will cover the latest studies on lithium use during breastfeeding and the most recent risk estimates for first-trimester exposure during pregnancy. By the end of the session, clinicians will be equipped with the knowledge needed to use lithium confidently and effectively in their practice.
Infertility and the treatments for it can be stressful, emotionally, and physically taxing, and can lead to anxiety, depression, grief, and other mental health issues. Reproductive endocrinology interventions, such as in vitro fertilization protocols, can also exacerbate underlying mood and anxiety conditions. The session will focus on identifying the psychological and neurochemical impact of infertility and reproductive endocrinology interventions, understanding the unique challenges faced by women in these situations, and exploring strategies for addressing and treating these mental health issues.
Developed in partnership with The International Society of Reproductive Psychiatry
Click to Read More
Designed to provide practical solutions to some of the most challenging patient cases, Solving Clinical Challenges sessions put our most experienced faculty on the spot to answer the question—what would you do? Exploring complex scenarios associated with real patients, our clinical panel will interact and collaborate to share insights and expertise on diagnostic challenges, psychopharmacologic and psychotherapeutic approaches, and multidisciplinary care. Practical take-aways will enable clinicians to apply advanced approaches to similarly complex patients, enhancing overall care delivery, and optimizing patient outcomes.
Click to Read More
Schizophrenia is a complex and heterogeneous disorder that affects approximately 1% of the population worldwide. Despite significant progress in the field, many questions remain about the underlying mechanisms of the disorder and the most effective interventions. This session will provide an overview of the latest research findings, including advances in genetic and neurobiological research, new diagnostic approaches, and emerging treatments.
Click to Read More
Addiction to video games, cybersex, internet gambling, social media, texting and emailing, and online auctions can be as addictive as substances. These technological addictions have real-world ramifications and lead to the loss of jobs, money, and loved ones. As technology becomes integrated into many facets of modern life, the appreciation of such addictions has become increasingly challenging. This session will explore the addictive potential of technology and discuss the legitimacy of technological addictions as psychiatric conditions worthy of medical assessment, diagnosis, and treatment.
Excessive daytime sleepiness (EDS), a symptom of many sleep disorders, including obstructive sleep apnea (OSA), disproportionately affects individuals with mental illness, increasing their risk of morbidity and mortality. EDS is associated with an increased risk of hospitalization, motor vehicle accidents, and cardiovascular disease and imposes significant burdens on individuals’ daytime functioning and overall well-being, commonly compromising cognitive functioning and impairing work and school productivity. This MasterClass session will explore the bidirectional relationship between sleep and psychiatric disorders and examine strategies to identify EDS and determine its root cause(s). Expert faculty will also explore the challenges surrounding effective treatment, which can have clinical repercussions for patients with co-morbid psychiatric disorders. Attendees will gain a greater understanding of appropriate treatment for individuals with co-occurring OSA and mental illness, positioning themselves to optimally manage OSA-associated EDS in these patients.
Click to Read More
Up to one-third of individuals experiencing MDD symptoms do not respond to treatment, and traditional antidepressants require weeks of administration before therapeutic effects are observed. This session is designed to empower psychiatric clinicians with the latest insights and practical skills for optimizing MDD treatment strategies. Throughout this session, expert faculty will delve into the assessment of current challenges inherent in the MDD treatment landscape, highlighting the necessity for innovative treatment approaches. Participants will gain a deep understanding of the current understanding of MDD pathophysiology and its intricate impact on various neurobiological systems. Attendees will then be equipped to evaluate the most recent safety and efficacy data associated with both current and emerging novel treatment options in MDD. This knowledge will enable participants to seamlessly incorporate novel treatment options into their clinical practice, aligning with the evolving MDD treatment paradigm.
Click to Read More
Schizophrenia is a serious mental health disorder associated with significant burdens, physical and psychological comorbidities, increased rates of mortality, and considerable therapeutic challenges. Conventional antipsychotic treatment for schizophrenia is plagued by numerous shortcomings, including inadequate treatment response and medication-related adverse events. Poor response and undesirable effects related to treatment are often a cause for patient-initiated and undisclosed treatment discontinuation. This session is designed to systematically address the myths and misconceptions that are limiting optimal use of LAIs for patients with schizophrenia by identifying the real-world data behind adherence challenges; providing up-to-date safety and efficacy data comparing LAIs with oral treatments; describing the most recent guideline recommendations for LAI therapy, including practical considerations and administration techniques; and providing strategies for communicating with patients about the opportunities and risks associated with LAI treatment for patients with schizophrenia, all with the goal of improving patient outcomes.
Click to Read More
Depressive Mixed States (DMX) is a condition where individuals experience both depressive symptoms and symptoms of mania or hypomania at the same time. In this session we will delve into the complexities of DMX and its diagnosis, as well as the available treatment options. A challenging diagnosis to make, it often presents with atypical symptoms that can be mistaken for other psychiatric conditions. However, understanding the clinical presentation of DMX is crucial for its accurate diagnosis and successful treatment.
Click to Read More
The healthcare industry is constantly changing, and navigating the complexities of Medicare, Medicaid, and private insurance can be challenging for psychiatric medical professionals. In this session, we will discuss the intricacies of third-party billing and coding, including common coding errors, reimbursement rules, and documentation requirements. We will also explore the potential pitfalls of non-compliance with insurance regulations and provide practical strategies for avoiding these pitfalls.
Click to Read More
Suicide is complex and there are several psychotherapy and medication treatment options available for clinicians to utilize. Relying on the latest available research, evidence-based treatments for reducing risk of suicidal behavior will be reviewed. The integration of psychotherapy and psychopharmacology for addressing suicide prevention will be discussed. How clinicians can Incorporate treatments and resources for suicide prevention into clinical practice will be described.
Developed in partnership with the American Foundation for Suicide Prevention.
Designed to provide practical solutions to some of the most challenging patient cases, Solving Clinical Challenges sessions put our most experienced faculty on the spot to answer the question—what would you do? Exploring complex scenarios associated with real patients, our clinical panel will interact and collaborate to share insights and expertise on diagnostic challenges, psychopharmacologic and psychotherapeutic approaches, and multidisciplinary care. Practical take-aways will enable clinicians to apply advanced approaches to similarly complex patients, enhancing overall care delivery, and optimizing patient outcomes.
Click to Read More
The goal of this session is to explore the role of psychiatric clinicians in chronic weight management. We will review the Anti-Obesity Medication (AOM) landscape and evidence-based guideline recommendations for incorporating AOMs as part of a comprehensive care plan, including lifestyle modifications. Real-world case studies of AOM use in psychiatric practice will be discussed. We will also review the proposed mechanism of action and clinical trial data for semaglutide, a GLP-1 receptor agonist approved to treat obesity in adults and adolescents as well as tirzepatide, a dual GLP-1 and GIP receptor agonist being investigated for treatment of obesity in adults.
This session aims to educate clinicians about the clinical clues and warning signs associated with homicide-suicide, a devastating phenomenon that continues to impact individuals and communities worldwide. With mass murders occurring frequently in the United States and an increasing number of Americans experiencing fear and anxiety related to violence in public spaces, it is essential for mental health professionals to be able to identify and respond to patients who may be at risk of engaging in these behaviors. This presentation will provide participants with practical strategies for assessing and managing patients who may be considering killing others before taking their own lives, including risk assessment tools and intervention techniques. Attendees will leave with a better understanding of how to recognize the clinical signs of homicide-suicide, as well as an increased ability to respond effectively to patients in crisis.
A number of psychedelic therapies are poised to have FDA approval this year, with more to come. These therapies represent exciting new ways of treating our patients, but also pose potential risks. The introduction of psychedelic assisted therapies (PAT) marks one of the most significant changes in available treatments for our patients. While much research has been conducted to get the treatments through the FDA, there is much that is still not known and will need to be considered when determining how to use these treatments. Complicating matters are the cultural and policy issues around psychedelics such as decriminalization and recreational use that may already be impacting our patients. This session, led by two expert researchers in the field, will attempt to disentangle these issues and prepare clinicians to thoughtfully deploy these treatments.
Click to Read More
Alzheimer's disease is a devastating neurodegenerative disorder that affects millions of individuals worldwide, with a significant impact on their quality of life and that of their caregivers. The aging of the population has made Alzheimer's disease a major public health concern, and as such, it is critical for medical professionals to stay up-to-date on the latest treatment strategies. This session will provide an overview of the latest research findings, including advances in pharmacological and non-pharmacological interventions and new diagnostic approaches.
Click to Read More
In this session, we will explore the importance of understanding autism spectrum disorder (ASD) as a fundamental skill for psychiatric practitioners. Autism is a complex neurological condition that affects communication, social interaction, and behavior. With the increasing prevalence of autism, it is crucial for psychiatric practitioners to have a good understanding of the disorder to provide optimal care and support for patients with ASD.
Click to Read More
Major depressive disorder (MDD) is a serious mental health condition that affects millions of people worldwide. Despite the availability of various treatments, a significant proportion of patients continue to experience symptoms of depression. Neuromodulation, a rapidly evolving field, is emerging as a promising approach for the treatment of MDD. This session will provide an overview of the latest advances in neuromodulation techniques, including deep brain stimulation, transcranial magnetic stimulation, and transcranial direct current stimulation.
Click to Read More
Pediatric anxiety disorders are one of the most common mental health conditions affecting children and adolescents. In recent years, there have been significant advances in our understanding and treatment of these disorders. The session will cover a range of topics including the identification and assessment of anxiety disorders in children and adolescents, the latest neurobiological findings, and evidence-based treatment approaches. Attendees will gain a deeper understanding of the latest developments in the field and leave with practical tools and strategies for working with children and families affected by anxiety disorders.
This session is designed to provide psychiatric medical professionals with insights on how to effectively manage telepsychiatry encounters with patients. With the increasing demand for virtual care, telepsychiatry has become a critical component of mental healthcare delivery. However, managing the telepsychiatry encounter comes with unique challenges, including navigating technological, regulatory, clinical and cultural barriers.
Click to Read More
Social relationships play a key role in etiology and pathophysiology of many psychiatric and general medical conditions. This session will review physiological underpinning of loneliness and social isolation and provide insight how it may contribute to development of psychiatric disorders. We will discuss how actively promoting better social interactions may be a key component of effective treatment plan for several psychiatric disorders and often a neglected part of their prevention.
With the implementation of the National Suicide Hotline Designation Act in 2020, mental health professionals and stakeholders are excited to discuss the potential benefits of having a three-digit number dedicated solely to crisis intervention and suicide prevention. The promise of 988 lies in its ability to provide easy access to emergency mental health services to anyone in need, regardless of their location or socio-economic status. This session will explore the implications of 988 and crisis care for the mental health community, including its impact on suicide prevention efforts, crisis stabilization, and access to care for vulnerable populations. The ways in which clinicians can integrate these services into their practice will be discussed.
Developed in partnership with the American Foundation for Suicide Prevention.
The most prescribed treatments for MDD are second-generation antidepressants. Given the variety of options in this medication class, tailoring treatment for MDD is a complex undertaking, requiring careful consideration of each agent’s unique efficacy, safety, and adverse effect profile, and an understanding of each patient’s individual characteristics and goals. Although symptomatic remission and full functional recovery are the overarching goals of treatment, a majority of patients treated for MDD continue to experience residual symptoms. In this session, expert faculty will explore the recognition and assessment of the impact of residual symptoms and treatment-emergent adverse events (TEAEs) on patients undergoing treatment for MDD. Attendees will learn to assess the limitations of traditional antidepressants for MDD, with a particular focus on how residual symptoms and TEAEs often contribute to relapse. By the end of the session, participants will possess the tools to mitigate residual symptoms and TEAEs effectively, enhancing treatment outcomes and patient well-being.
Click to Read More
While there has been some progress in developing therapeutics for schizophrenia, the overall trajectory has been uninspiring, with endless variations of ways to manipulate the D2 receptor. There are however some novel agents which have potential to transform the schizophrenia treatment landscape. Participate in this session to explore mechanisms of action (MOAs) of novel and investigational agents, such as TAAR1 agonists, M1/M4 receptor agonists, and VMAT2 inhibitors, and how they hold promise in addressing limitations of conventional treatments. Expert faculty will critically evaluate the most recent clinical trial data pertaining to the safety, tolerability, and efficacy of these emerging agents for patients with schizophrenia.
Click to Read More
Did you know that over half of patients with Parkinson disease will experience symptoms of psychosis and as many as 80% of patients with advanced PD experience hallucinations and delusions, regardless of the presence of age-associated dementia? Navigating the treatment of this complex disease can be difficult due to competing treatment paradigms with medications designed to help motor function negatively impacting emotions and behaviors. In this MasterClass session, expert faculty will critically evaluate the mechanism of action, clinical trial data, and real-world safety/efficacy data for current, emerging, and off-label therapies for PDP. Furthermore, they will discuss the implementation of multidisciplinary approaches to optimize care for patients with Parkinson's disease and PDP, emphasizing effective communication strategies and shared decision-making with patients and care partners. By the end of the session, participants will have gained valuable knowledge and skills to improve the care and outcomes of patients with PDP.
Click to Read More
The opioid epidemic continues to ravage communities across the country, with many individuals struggling with opioid use disorder (OUD). Medication-assisted therapy (MAT) with buprenorphine has emerged as a gold standard treatment for OUD. However, access to this treatment has been limited due to the requirement of an X-waiver for healthcare providers to prescribe Buprenorphine.
Click to Read More
As clinicians, we all want to better serve our patients but sadly, mental health outcomes are lackluster at best. As the story of psychedelic-assisted therapy began to circulate, we were excited about the possibilities. Even though the field is rapidly developing, opinions about psychedelic-assisted psychotherapy vary as do outcomes. Additionally, there is a lack of standardized protocols and training. This session will explore the world of psychedelic-assisted psychotherapy, the practice of combining psychedelics with therapeutic techniques for healing. We will delve into the history of psychedelic-assisted therapy, its practical applications, and some promising results in using this approach in treating mental health conditions. Ethical considerations and future directions will also be discussed.
Developed in partnership with SANA
Click to Read More
In this session, we will explore bi-directional relationships between inflammation and depression, shedding light on how inflammation can give rise to a distinct form of major depressive disorder. We will examine compelling evidence showcasing the limitations of anti-inflammatory agents as universal antidepressants. We will also explore how inflammatory biomarkers can be harnessed to aid in making more precise psychopharmacologic treatment decisions, allowing for personalized and effective care. You will gain valuable insights to enhance your understanding of the complex interplay between inflammation and depression, guiding your future treatment approaches with greater precision and efficacy.
ADHD is a neurodevelopmental disorder that can have a significant impact on an individual's academic, social, and occupational functioning. However, the symptoms and challenges associated with ADHD can shift and evolve as an individual progresses through different stages of development. In this session, we will explore the unique challenges and opportunities associated with ADHD during the transition from childhood to adulthood, including issues related to medication management, executive functioning, social skills, and career development. We will also discuss strategies for supporting individuals with ADHD as they navigate this critical transition period. By the end of this session, attendees will have a deeper understanding of the complexities of ADHD across the lifespan and be better equipped to provide effective, evidence-based care to individuals with ADHD.
Social media platforms are now used by billions of people worldwide. Although these platforms are suggested as opportunities for entertainment and social connection, numerous studies provide strong evidence that social media use can increase feelings of anxiety, depression, low self-esteem, and isolation. Particularly for adolescents, social media platforms can carry serious risks, such as cyberbullying, suicide, self-harm, sexualization, disrupted identity development, and impaired relationship formation. This session will explore the impact of social media platforms on mental health and suggest practical approaches for how clinicians can approach this topic with patients.
Attention Deficit Hyperactivity Disorder (ADHD), Bipolar Disorder (BPD), and Treatment Resistant Depression (TRD) are three psychiatric conditions that often present with similar symptoms, making accurate diagnosis challenging for clinicians. This session will provide a comprehensive overview of the differential diagnosis of ADHD and highlight the nuances involved in identifying and differentiating ADHD from other psychiatric and neurological conditions that may present with similar symptoms. Participants will gain an understanding of the various diagnostic tools and methods used in clinical practice to accurately diagnose ADHD, including clinical interviews, rating scales, and neuropsychological assessments.
The Covid-19 pandemic has had a significant impact on the mental health of individuals worldwide, including healthcare professionals who have been at the forefront of the response effort. In this session, we will explore the impact of the pandemic on clinician burnout and discuss strategies to address this issue in a post-Covid world.
Click to Read More
In this session, we will explore the complexities of balancing psychiatric treatments with lifestyle considerations, such as the tradeoffs between medication adverse reactions like weight gain and tremors. We will discuss how to find an acceptable balance for each patient and consider the whole health of the individual rather than solely addressing their presenting issue.
Developed in partnership with Depression and Bipolar Support Alliance
Click to Read More
This session will focus on the importance of diagnostic accuracy in treating individuals with Treatment Resistant Depression (TRD) or Bipolar Disorder. These conditions can be challenging to diagnose accurately, and misdiagnosis can lead to inadequate treatment or worsening of symptoms. The session will discuss the common symptoms and diagnostic criteria for TRD and BD, as well as the challenges clinicians face in differentiating between the two disorders.
Click to Read More
Join the Psych Congress Steering Committee, attendees, and peers for a poster reception and awards ceremony.
Advocacy can bring about significant positive change for mental health care providers and their patients. It can improve access to care, increase funding for mental health services, and promote better mental health policies. By sharing stories of successful advocacy campaigns, we hope to inspire attendees to become more involved in advocacy efforts and make a difference in their communities. We will also discuss practical ways to get people more involved in advocacy, such as forming coalitions, using social media, and reaching out to local lawmakers. By the end of this session, attendees will be equipped with the knowledge and tools they need to become effective advocates for mental health care in their communities.
Developed in partnership with Depression and Bipolar Support Alliance
Click to Read More
The use of medical marijuana has gained significant attention and controversy in recent years. In this session, we will explore the current state of the science of cannabis and its use as medical marijuana, including its potential benefits, risks, and interactions with medications. This session aims to provide attendees with a comprehensive understanding of the current landscape of medical marijuana and equip them with the knowledge they need to make informed decisions about its use.
Atypical antipsychotics are commonly prescribed for the treatment of various psychiatric disorders, but their use can be associated with a range of adverse effects. The session will cover the most common side effects associated with atypical antipsychotics, including metabolic disturbances, movement disorders, and cardiovascular complications. Strategies for managing these side effects, such as prescribing adjunctive medications, lifestyle modifications, and patient education will be discussed. Participants will leave this session with a deeper understanding of the side effects of atypical antipsychotics and the skills to effectively manage them in their clinical practice.
Brunch will be served. Seating will be limited.
The session will begin with a unique poster review before expert faculty dive into the lecture. Grab a headset and take a tour of 3 different posters, each highlighting current data on TAAR1 agonists. The lecture portion of this session will begin by discussing the limitations and barriers associated with the use of antipsychotics for schizophrenia whose MOA centers on dopamine D2 binding. Expert faculty will evaluate the mechanism of action and safety/efficacy data associated with TAAR1 agonism in the management of schizophrenia, followed by a discussion of potential clinical implications for TAAR1 agonists and how to identify and educate patients who might benefit from these novel therapies.
Click to Read More
Individuals with bipolar disorder are at a higher risk of developing substance use disorders, which can significantly complicate the management of their bipolar symptoms. The session will provide an overview of the prevalence and impact of co-occurring substance use and bipolar disorder, explore the complex interplay between substance use and bipolar disorder, including how substance use can trigger or exacerbate bipolar symptoms, and examine how bipolar disorder can increase the risk of substance use.
Click to Read More
As the population continues to age, the prevalence of both depression and dementia in older adults is expected to increase. For psychiatric medical professionals, the management of these dual challenges can be complex and require a nuanced approach. This session will explore the intersection of geriatric depression and dementia and provide practical guidance in the assessment, diagnosis, and treatment of these conditions.
Click to Read More
Long-acting injectable (LAI) medications have become an essential tool in the management of schizophrenia, particularly in patients with poor medication adherence and/or a history of frequent hospitalizations. This session will explore the benefits of LAIs, including improved symptom control, reduced hospitalization rates, and increased quality of life, through a discussion from panelists, including that from the perspective of an ACT team. The ACT team, or Assertive Community Treatment team, is a specialized type of multidisciplinary mental health care team that provides intensive and comprehensive treatment to individuals with severe and persistent mental illnesses who have complex and often multiple needs. The team uses a patient-centered approach, and works closely with patients and their families to develop individualized treatment plans that are tailored to meet each patient's unique needs and goals.
Click to Read More
Music moves us, music uplifts us. Music accompanies us from birth to death. But, does music have a role in mental health and mental wellness? This presentation will examine the deep neurobiology of music and its clinical application in various disorders in psychiatry - ranging from autism to dementia, spanning from the young to the old, and as therapy and as a prophylactic to preventing depression and anxiety disorders. This presentation will extensively use music clips to demonstrate various applications of music in our clinical practices.
Join Psych Congress 2023 Co-Chairs and the entire Steering Committee for an interactive “wrap-up” and panel discussion focusing on conference highlights from the previous 4 days of educational sessions.